Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.48 |
| ▸ | ABL1 | P00519 | 10/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15260016 | 0.87 | ABL1 (0.59) | PIK3CDABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15260152 | 0.85 | ABL1 (0.51) | PIK3CDABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3661848 | 0.84 | ABL1 (0.48) | PIK3CDABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16975370 | 0.84 | PIK3CD (0.45) | PIK3CDABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15260115 | 0.83 | ABL1 (0.50) | PIK3CDABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3664150 | 0.82 | ABL1 (0.53) | PIK3CDABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3658741 | 0.82 | ABL1 (0.53) | PIK3CDABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15260275 | 0.82 | ABL1 (0.48) | ABL1 | |
| SCHEMBL15260177 | 0.82 | ABL1 (0.45) | PIK3CDABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15260205 | 0.82 | ABL1 (0.45) | PIK3CDABL1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170260178-A1 | ANTIBACTERIAL COMPOUNDS | SPERO GYRASE INC (US) | 2017-09-14 | — | — | US | claimed |
| US-20150329530-A1 | ANTIBACTERIAL COMPUNDS | SPERO GYRASE, INC. | 2015-11-19 | — | — | US | claimed |
| EP-2828257-A1 | ANTIBACTERIAL COMPOUNDS | Biota Europe Ltd (GB) | 2015-01-28 | — | — | EP | claimed |
| US-8906902-B2 | Antibacterial compounds | BIOTA EUROPE LIMITED (GB) | 2014-12-09 | — | — | US | claimed |
| US-20130252938-A1 | Antibacterial Compounds | BIOTA EUROPE LTD. (GB) | 2013-09-26 | — | — | US | claimed |
| WO-2013138860-A1 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LIMITED (GB) | 2013-09-26 | — | — | WO | claimed |
| US-20170260178-A1 | ANTIBACTERIAL COMPOUNDS | SPERO GYRASE INC (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170260178-A1 | ANTIBACTERIAL COMPOUNDS | SPERO GYRASE INC (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170260178-A1 | ANTIBACTERIAL COMPOUNDS | SPERO GYRASE INC (US) | 2017-09-14 | — | — | US | disclosed |
| EP-2828257-B1 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LTD (GB) | 2017-07-26 | — | — | EP | disclosed |
| EP-2828257-B1 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LTD (GB) | 2017-07-26 | — | — | EP | disclosed |
| US-9604976-B2 | Antibacterial compounds | SPERO GYRASE, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9604976-B2 | Antibacterial compounds | SPERO GYRASE, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-8906902-B2 | Antibacterial compounds | BIOTA EUROPE LIMITED (GB) | 2014-12-09 | — | — | US | disclosed |
| US-8906902-B2 | Antibacterial compounds | BIOTA EUROPE LIMITED (GB) | 2014-12-09 | — | — | US | disclosed |
| US-8906902-B2 | Antibacterial compounds | BIOTA EUROPE LIMITED (GB) | 2014-12-09 | — | — | US | disclosed |
| US-20130252938-A1 | Antibacterial Compounds | BIOTA EUROPE LTD. (GB) | 2013-09-26 | — | — | US | disclosed |
| US-20130252938-A1 | Antibacterial Compounds | BIOTA EUROPE LTD. (GB) | 2013-09-26 | — | — | US | disclosed |
| US-20130252938-A1 | Antibacterial Compounds | BIOTA EUROPE LTD. (GB) | 2013-09-26 | — | — | US | disclosed |
| WO-2013138860-A1 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LIMITED (GB) | 2013-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170260178-A1 | ANTIBACTERIAL COMPOUNDS | STS, PGLS, PEPD | PIK3CD 289/4885ABL1 1389/4885NPC1 1870/4885 |
| US-20150329530-A1 | ANTIBACTERIAL COMPUNDS | STS, PEPD, PGLS | PIK3CD 419/4885ABL1 1764/4885NPC1 2454/4885 |
| US-20130252938-A1 | Antibacterial Compounds | STS, PGLS, PEPD | PIK3CD 289/4885ABL1 1389/4885NPC1 1870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.